No FDA Compromise On Veregen Specifications In First Botanical NDA Review

The first botanical NDA, MediGene’s Veregen (kunecatechins), illuminated gaps in the emerging regulatory framework for plant-derived prescription drugs, FDA review documents indicate.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet